Contents

EBM analysis

Mental health
191 The ‘double whammy’ of low prevalence in clinical risk prediction

General medicine
195 Early experience with the FDA’s regulatory review of novel gene therapies
199 Transparency of COVID-19 vaccine trials: decisions without data

EBM opinion and debate

General medicine
206 Colorectal cancer screening at a younger age: pitfalls in the model-based recommendation of the USPSTF

EBM learning
209 Data-dredging bias
212 Appraising qualitative health research—towards a differentiated approach

Evidence synthesis
215 Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis

224 Ivabradine added to usual care in patients with heart failure: a systematic review with meta-analysis and trial sequential analysis

235 Interventions for Ménière’s disease: an umbrella systematic review

Research methods and reporting
246 Later is not necessarily better: limitations of survival analysis in studies of long-term drug treatment of psychiatric conditions

Miscellaneous
251 Correction: Developing future leaders in evidence-based medicine: the inaugural David Sackett Fellowship